LT2889033T - Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis - Google Patents

Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis

Info

Publication number: LT2889033T
Authority: LT; Lithuania
Prior art keywords: quinuclidin; schizophrenia; carboxamide; thiophene; benzo
Prior art date: 2008-11-19

Application number

LTEP15151165.6T

Other languages

English (en)

Inventor

Gerhard Koenig

Richard Chesworth

Gideon Shapiro

Original Assignee

Forum Pharmaceuticals Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-19

Filing date

2009-11-19

Publication date

2018-07-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41786120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2889033(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-11-19 Application filed by Forum Pharmaceuticals Inc. filed Critical Forum Pharmaceuticals Inc.

2018-07-10 Publication of LT2889033T publication Critical patent/LT2889033T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LTEP15151165.6T 2008-11-19 2009-11-19 Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis LT2889033T (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11610608P	2008-11-19	2008-11-19

Publications (1)

Publication Number	Publication Date
LT2889033T true LT2889033T (lt)	2018-07-10

Family

ID=41786120

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP15151165.6T LT2889033T (lt)	2008-11-19	2009-11-19	Šizofrenijos negatyvių simptomų gydymas (r)-7-chlor-n-(chinuklidin-3-il)benzo[b]tiofen-2-karboksamidu ir jo farmaciniu požiūriu priimtinomis druskomis

Country Status (34)

Country	Link
US (6)	US8642638B2 (lt)
EP (4)	EP2355822B1 (lt)
JP (6)	JP5272080B2 (lt)
KR (3)	KR20140146216A (lt)
CN (3)	CN105687190A (lt)
AU (1)	AU2009316557B2 (lt)
BR (1)	BRPI0922057A2 (lt)
CA (3)	CA2744278C (lt)
CL (3)	CL2011001178A1 (lt)
CO (1)	CO6400190A2 (lt)
CR (1)	CR20110267A (lt)
CY (3)	CY1113671T1 (lt)
DK (3)	DK2889033T3 (lt)
EC (1)	ECSP11011076A (lt)
ES (3)	ES2673016T3 (lt)
HR (3)	HRP20130007T1 (lt)
HU (2)	HUE037938T2 (lt)
IL (5)	IL212921A (lt)
LT (1)	LT2889033T (lt)
MX (1)	MX2011005270A (lt)
MY (2)	MY159826A (lt)
NZ (2)	NZ593467A (lt)
PE (1)	PE20110711A1 (lt)
PH (2)	PH12014501629A1 (lt)
PL (3)	PL2355822T3 (lt)
PT (3)	PT2355822E (lt)
RS (1)	RS52583B (lt)
RU (3)	RU2532327C2 (lt)
SG (1)	SG10201504102QA (lt)
SI (3)	SI2889033T1 (lt)
SM (3)	SMT201800308T1 (lt)
TR (1)	TR201807944T4 (lt)
WO (1)	WO2010059844A1 (lt)
ZA (1)	ZA201104044B (lt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
AU2009316557B2 (en)	2008-11-19	2015-08-27	Envivo Pharmaceuticals, Inc.	Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl) benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
CA2799744C (en)	2010-05-17	2020-01-28	Envivo Pharmaceuticals, Inc.	A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
WO2012074799A1 (en) *	2010-11-18	2012-06-07	Envivo Pharmaceuticals, Inc.	Treatment of inflammation with certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors
US20140155429A1 (en) *	2011-05-09	2014-06-05	Envivo Pharmaceuticals, Inc.	Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine
RU2014103474A (ru) *	2011-07-01	2015-08-10	Энвиво Фармасьютикалз, Инк.	Способы лечения умеренных когнитивных нарушений
US9585877B2 (en) *	2012-05-08	2017-03-07	Forum Pharmaceuticals, Inc.	Methods of maintaining, treating or improving cognitive function
JP7170670B2 (ja)	2017-02-27	2022-11-14	ユニヴァーシティオブピッツバーグオブザコモンウェルスシステムオブハイアーエデュケイション	抗精神病組成物及び治療方法
EP3684463B1 (en)	2017-09-19	2025-05-14	Neuroenhancement Lab, LLC	Method and apparatus for neuroenhancement
US11717686B2 (en)	2017-12-04	2023-08-08	Neuroenhancement Lab, LLC	Method and apparatus for neuroenhancement to facilitate learning and performance
US11273283B2 (en)	2017-12-31	2022-03-15	Neuroenhancement Lab, LLC	Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en)	2017-12-31	2025-04-22	NeuroLight, Inc.	Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en)	2018-04-20	2022-06-21	Neuroenhancement Lab, LLC	System and method for inducing sleep by transplanting mental states
CA3112564A1 (en)	2018-09-14	2020-03-19	Neuroenhancement Lab, LLC	System and method of improving sleep

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5122528A (en)	1983-12-22	1992-06-16	Erbamont, Inc.	Analgesic use of benzobicyclic carboxamides
US4605652A (en)	1985-02-04	1986-08-12	A. H. Robins Company, Inc.	Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
EP0201165B1 (en)	1985-03-14	1994-07-20	Beecham Group Plc	Medicaments for the treatment of emesis
NL8701682A (nl)	1986-07-30	1988-02-16	Sandoz Ag	Werkwijze voor het therapeutisch toepassen van serotonine antagonisten, aktieve verbindingen en farmaceutische preparaten die deze verbindingen bevatten.
DE3827253A1 (de)	1987-08-20	1989-03-02	Sandoz Ag	Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE3740984A1 (de)	1987-12-03	1989-06-15	Sandoz Ag	N-oxide von heterocyclischen carbonsaeurederivaten bzw. verfahren zu deren herstellung und deren verwendung
US5198437A (en)	1987-12-10	1993-03-30	Duphar International Research B.V.	1,7-annelated indolecarboxylic acid esters and amides
ZA889166B (en)	1987-12-10	1990-05-30	Duphar Int Res	1,7-annelated indolecarboxylic acid esters and -amides
US4863919A (en)	1988-02-01	1989-09-05	A. H. Robins Company, Incorporated	Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
DE3810552A1 (de)	1988-03-29	1989-10-19	Sandoz Ag	Ester und amide von indol-, benzo(b)thiopen-, benzo(b)furancarbonsaeuren oder 4-amino-2-methoxy-benzolsaeuren mit n-heterocyclischen oder n-heterobicyclischen alkoholen oder aminen, verfahren zu deren herstellung sie enthaltende pharmazeutische zusammensetzungen sowie applikator zur verabreichung derselben
EP0353371A1 (en)	1988-08-04	1990-02-07	Synthelabo	Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
IE62662B1 (en)	1989-01-06	1995-02-22	Elan Corp Plc	Use of nicotine in the treatment of conditions susceptible to said treatment
US5189041A (en)	1990-11-16	1993-02-23	Syntex (U.S.A.) Inc.	Tricyclic 5-ht3 receptor antagonists
US5114947A (en)	1990-12-27	1992-05-19	Erbamont Inc.	Method for alleviating anxiety using benzobicyclic carboxamides
DE4115215A1 (de)	1991-05-10	1992-11-12	Merck Patent Gmbh	Indolderivate
SE9201478D0 (sv)	1992-05-11	1992-05-11	Kabi Pharmacia Ab	Heteroaromatic quinuclidinenes, their use and preparation
US5977144A (en)	1992-08-31	1999-11-02	University Of Florida	Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
PT777671E (pt)	1994-08-24	2000-08-31	Astrazeneca Ab	Compostos espiro-azabiciclicos uteis em terapia
US5760062A (en)	1995-04-18	1998-06-02	Geron Corporation	Telomerase inhibitors
US5703116A (en)	1995-04-18	1997-12-30	Geron Corporation	Telomerase Inhibitors
US5863936A (en)	1995-04-18	1999-01-26	Geron Corporation	Telomerase inhibitors
US5656638A (en)	1995-04-18	1997-08-12	Geron Corporation	Telomerase inhibitors
GB9606736D0 (en)	1996-02-19	1996-06-05	Shire International Licensing	Therapeutic method
FR2756826B1 (fr)	1996-12-05	1999-01-08	Adir	Nouveaux derives tetrahydropyridiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK0984965T3 (da)	1997-05-30	2004-09-27	Neurosearch As	8-azabicyclo[3.2.1]oct-2-enderivater som cholinerge ligander ved nikotin-ACh-receptorer
US7214686B2 (en)	1997-06-30	2007-05-08	Targacept, Inc.	Pharmaceutical compositions and methods for effecting dopamine release
JPH1180027A (ja)	1997-09-12	1999-03-23	Dai Ichi Seiyaku Co Ltd	向知性薬
US6875606B1 (en)	1997-10-23	2005-04-05	The United States Of America As Represented By The Department Of Veterans Affairs	Human α-7 nicotinic receptor promoter
US6277870B1 (en)	1998-05-04	2001-08-21	Astra Ab	Use
CA2343320A1 (en)	1998-09-18	2000-03-30	The Rockefeller University	Lynx, a novel family of receptor ligands in the central nervous system, corresponding nucleic acids and proteins and uses therof
US6953855B2 (en)	1998-12-11	2005-10-11	Targacept, Inc.	3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en)	1998-12-11	2002-08-13	Targacept, Inc.	Pharmaceutical compositions and methods for use
SE9900100D0 (sv)	1999-01-15	1999-01-15	Astra Ab	New compounds
FR2790474B1 (fr)	1999-03-05	2001-04-06	Synthelabo	Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
FR2791678B1 (fr)	1999-03-30	2001-05-04	Synthelabo	Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique
US6416735B1 (en)	1999-11-08	2002-07-09	Research Triangle Institute	Ligands for α-7 nicotinic acetylcholine receptors based on methyllcaconitine
AU1920401A (en)	1999-12-01	2001-06-12	Ortho-Mcneil Pharmaceutical, Inc.	Method of diagnosing neurodegenerative disease
CA2393538A1 (en)	1999-12-14	2001-06-21	Pharmacia & Upjohn Company	Human ion channels
FR2804430B1 (fr)	2000-01-28	2002-03-22	Sanofi Synthelabo	Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en)	2000-05-05	2000-06-28	Novartis Ag	Organic compounds
WO2001094353A1 (en)	2000-06-06	2001-12-13	Pfizer Products Inc.	Thiophene derivatives useful as anticancer agents
TW593223B (en)	2000-06-20	2004-06-21	Merz Pharma Gmbh & Co Kgaa	1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
FR2810664B1 (fr)	2000-06-27	2004-12-24	Adir	Nouveaux composes cyclopropaniques 1,1 et 1,2-dissubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4616971B2 (ja)	2000-07-18	2011-01-19	田辺三菱製薬株式会社	１−アザビシクロアルカン化合物およびその医薬用途
US20030092613A1 (en)	2000-08-14	2003-05-15	Lee Daniel H. S.	Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
US6492385B2 (en)	2000-08-18	2002-12-10	Pharmacia & Upjohn Company	Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002016358A2 (en)	2000-08-18	2002-02-28	Pharmacia & Upjohn Company	Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
US6492386B2 (en)	2000-08-18	2002-12-10	Pharmacia & Upjohn Company	Quinuclidine-substituted aryl compounds for treatment of disease
WO2002017358A2 (en)	2000-08-21	2002-02-28	Pharmacia & Upjohn Company	Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
DE10044905A1 (de)	2000-09-12	2002-03-21	Merck Patent Gmbh	(2-Azabicyclo[2.2.1]hept-7-yl)methanol-Derivate als nikontinische Acetylcholinrezeptor Agonisten
US20020086871A1 (en)	2000-12-29	2002-07-04	O'neill Brian Thomas	Pharmaceutical composition for the treatment of CNS and other disorders
EP1231212B1 (en)	2001-02-06	2006-12-20	Pfizer Products Inc.	Pharmaceutical compositions for the treatment of disorders of the CNS and other disorders
GB0108337D0 (en)	2001-04-03	2001-05-23	Novartis Ag	Organic compounds
US6569865B2 (en)	2001-06-01	2003-05-27	Astrazeneca Ab	Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AR036040A1 (es)	2001-06-12	2004-08-04	Upjohn Co	Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
JP2005504059A (ja)	2001-08-24	2005-02-10	ファルマシアアンドアップジョンカンパニーリミティドライアビリティーカンパニー	疾患を処置するための置換アリール７−アザ［２．２．１］ビシクロヘプタン
JP2003081978A (ja)	2001-09-10	2003-03-19	Mitsubishi Pharma Corp	スピロ環式化合物およびその医薬用途
ATE355293T1 (de)	2001-09-12	2006-03-15	Pharmacia & Upjohn Co Llc	Substituierte 7-aza-(2.2.1)bicycloheptane für die behandlung von krankheiten
EP1432707B1 (en)	2001-10-02	2012-03-28	Pharmacia & Upjohn Company LLC	Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
WO2003037896A1 (en)	2001-10-26	2003-05-08	Pharmacia & Upjohn Company	N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists
WO2003040147A1 (en)	2001-11-08	2003-05-15	Pharmacia & Upjohn Company	Azabicyclic-substituted-heteroaryl compounds for the treatment of disease__________________________________________________________________________________________________________________________
JP2005510523A (ja)	2001-11-09	2005-04-21	ファルマシアアンドアップジョンカンパニーリミティドライアビリティーカンパニー	アザ二環式フェニル縮合複素環式化合物、及びα７ＮＡＣＨＲリガンドとしての当該化合物の使用
GB0127008D0 (en)	2001-11-09	2002-01-02	Novartis Ag	Organic compounds
DE10156719A1 (de)	2001-11-19	2003-05-28	Bayer Ag	Heteroarylcarbonsäureamide
FR2832712B1 (fr)	2001-11-23	2004-02-13	Sanofi Synthelabo	Derives de 4-(oxadiazol-3-yl)-1,4-diazabicyclo[3.2.2]nonane, leur preparation et leur application en therapeutique
FR2832713B1 (fr)	2001-11-23	2004-02-13	Sanofi Synthelabo	Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
FR2832714B1 (fr)	2001-11-23	2004-07-16	Sanofi Synthelabo	Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
AU2002360598B2 (en)	2001-12-14	2008-02-14	Medical College Of Georgia Research Institute, Inc.	Methods and compositions for treatment of central nervous system disorders
DE10162375A1 (de)	2001-12-19	2003-07-10	Bayer Ag	Bicyclische N-Aryl-amide
DE10162442A1 (de)	2001-12-19	2003-07-03	Bayer Ag	Monocyclische N-Aryl-amide
DE10164139A1 (de)	2001-12-27	2003-07-10	Bayer Ag	2-Heteroarylcarbonsäureamide
US6852716B2 (en)	2002-02-15	2005-02-08	Pfizer Inc	Substituted-aryl compounds for treatment of disease
US6894042B2 (en)	2002-02-19	2005-05-17	Pharmacia & Upjohn Company	Azabicyclic compounds for the treatment of disease
US6858613B2 (en)	2002-02-19	2005-02-22	Pfizer Inc.	Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
CA2475773A1 (en)	2002-02-20	2003-09-04	Pharmacia & Upjohn Company	Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
DE10211416A1 (de)	2002-03-15	2003-09-25	Bayer Ag	Essig- und Propionsäureamide
DE10211415A1 (de)	2002-03-15	2003-09-25	Bayer Ag	Bicyclische N-Biarylamide
US20030236287A1 (en)	2002-05-03	2003-12-25	Piotrowski David W.	Positive allosteric modulators of the nicotinic acetylcholine receptor
AU2003267174A1 (en)	2002-05-09	2003-11-11	Memory Pharmaceuticals Corporation	Qm-7 and qt-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
JP2006503811A (ja)	2002-07-17	2006-02-02	ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー	アロステリックカルボキシルマトリックスメタロプロテイナーゼ−１３阻害薬とセレコキシブまたはバルデコキシブとの組み合わせ
DE10234424A1 (de)	2002-07-29	2004-02-12	Bayer Ag	Benzothiophen-, Benzofuran- und Indolharnstoffe
AU2003253186A1 (en)	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
MXPA05001642A (es)	2002-08-13	2005-04-25	Warner Lambert Co	Derivados de naftaleno como inhibidores de metaloproteinasas de matriz.
GB0220581D0 (en)	2002-09-04	2002-10-09	Novartis Ag	Organic Compound
AU2003276919B2 (en)	2002-09-25	2013-05-16	Memory Pharmaceuticals Corporation	Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
CA2508004A1 (en)	2002-12-11	2004-06-24	Pharmacia & Upjohn Company Llc	Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
US20050031651A1 (en)	2002-12-24	2005-02-10	Francine Gervais	Therapeutic formulations for the treatment of beta-amyloid related diseases
BRPI0408815A (pt)	2003-03-28	2006-04-04	Pharmacia & Upjohn Co Llc	moduladores alostéricos positivos do receptor nicotìnico da acetilcolina
US20050119249A1 (en)	2003-12-02	2005-06-02	Erik Buntinx	Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050245531A1 (en)	2003-12-22	2005-11-03	Abbott Laboratories	Fused bicycloheterocycle substituted quinuclidine derivatives
US20050234095A1 (en)	2004-03-25	2005-10-20	Wenge Xie	Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
AU2004325725A1 (en)	2004-12-10	2006-06-22	Abbott Laboratories	Fused bicycloheterocycle substituted quinuclidine derivatives
AU2006295397A1 (en)	2005-09-23	2007-04-05	Memory Pharmaceuticals Corporation	Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
ES2633318T3 (es)	2006-10-23	2017-09-20	Cephalon, Inc.	Derivados bicíclicos fusionados de 2,4-diaminopirimidina como inhibidores de ALK y c-Met
PT2152712E (pt)	2007-05-11	2012-02-29	Pfizer	Compostos amino-heterocíclicos
EP2181992B8 (en)	2007-08-31	2013-06-26	Eisai R&D Management Co., Ltd.	Polycyclic compound
US7935815B2 (en)	2007-08-31	2011-05-03	Eisai R&D Management Co., Ltd.	Imidazoyl pyridine compounds and salts thereof
DK2217597T3 (da)	2007-10-01	2011-06-20	Comentis Inc	Quinuclidin-4-ylmethyl-1h-indol-3-carboxylatderivater som alpha-7-nicotin-acetylcholin-receptor-ligander til behandling af Alzheimers sygdom
MX2010005648A (es)	2007-11-21	2010-06-02	Abbott Lab	Derivados de alcano azabiciclico sustituidos con biarilo como moduladores de la actividad del receptor nicotinico de acetilcolina.
EA021731B1 (ru)	2008-04-29	2015-08-31	Фарнекст	Новые композиции для лечения болезни альцгеймера
BRPI0911874A2 (pt)	2008-04-29	2018-05-22	Pharnext	composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato
EP2282779B1 (en)	2008-04-29	2013-03-13	Pharnext	New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response
AU2009313927A1 (en)	2008-11-13	2010-05-20	Astrazeneca Ab	Azaquinolinone derivatives and uses thereof
AU2009316557B2 (en)	2008-11-19	2015-08-27	Envivo Pharmaceuticals, Inc.	Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl) benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
WO2010071846A2 (en)	2008-12-19	2010-06-24	Afraxis, Inc.	Compounds for treating neuropsychiatric conditions
WO2010075635A1 (en)	2008-12-30	2010-07-08	Ramot At Tel Aviv University Ltd.	Combination therapies using nap
TWI404721B (zh)	2009-01-26	2013-08-11	Pfizer	胺基－雜環化合物
DK3395372T3 (da)	2009-02-20	2022-04-19	Enhanx Biopharm Inc	System til afgivelse af glutathion-baseret medikament
CN102333777B (zh)	2009-02-26	2014-06-25	卫材R&D管理有限公司	含氮的稠合杂环化合物及其作为β淀粉样蛋白生成抑制剂的用途
MX2011010782A (es)	2009-04-13	2012-01-20	Theravance Inc	Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
JP2012529432A (ja)	2009-06-05	2012-11-22	リンク・メディスン・コーポレーション	アミノピロリジノン誘導体及びその使用
US20110262442A1 (en)	2009-11-06	2011-10-27	Adenios, Inc.	Compositions for treating cns disorders
US20110274628A1 (en)	2010-05-07	2011-11-10	Borschke August J	Nicotine-containing pharmaceutical compositions

2009
- 2009-11-19 AU AU2009316557A patent/AU2009316557B2/en not_active Ceased
- 2009-11-19 ES ES15151165.6T patent/ES2673016T3/es active Active
- 2009-11-19 DK DK15151165.6T patent/DK2889033T3/en active
- 2009-11-19 KR KR1020147032489A patent/KR20140146216A/ko not_active Ceased
- 2009-11-19 LT LTEP15151165.6T patent/LT2889033T/lt unknown
- 2009-11-19 CN CN201610020803.2A patent/CN105687190A/zh active Pending
- 2009-11-19 HR HRP20130007AT patent/HRP20130007T1/hr unknown
- 2009-11-19 PT PT97569214T patent/PT2355822E/pt unknown
- 2009-11-19 BR BRPI0922057A patent/BRPI0922057A2/pt not_active Application Discontinuation
- 2009-11-19 HU HUE15151165A patent/HUE037938T2/hu unknown
- 2009-11-19 SI SI200931855T patent/SI2889033T1/en unknown
- 2009-11-19 TR TR2018/07944T patent/TR201807944T4/tr unknown
- 2009-11-19 ES ES09756921T patent/ES2396300T3/es active Active
- 2009-11-19 NZ NZ593467A patent/NZ593467A/xx not_active IP Right Cessation
- 2009-11-19 PE PE2011001056A patent/PE20110711A1/es not_active Application Discontinuation
- 2009-11-19 MY MYPI2011002245A patent/MY159826A/en unknown
- 2009-11-19 WO PCT/US2009/065173 patent/WO2010059844A1/en not_active Ceased
- 2009-11-19 PL PL09756921T patent/PL2355822T3/pl unknown
- 2009-11-19 EP EP09756921A patent/EP2355822B1/en active Active
- 2009-11-19 RU RU2011124515/15A patent/RU2532327C2/ru not_active IP Right Cessation
- 2009-11-19 DK DK09756921.4T patent/DK2355822T3/da active
- 2009-11-19 RS RS20120560A patent/RS52583B/sr unknown
- 2009-11-19 CA CA2744278A patent/CA2744278C/en not_active Expired - Fee Related
- 2009-11-19 MY MYPI2014003208A patent/MY173229A/en unknown
- 2009-11-19 CN CN201610021941.2A patent/CN105687191A/zh active Pending
- 2009-11-19 SG SG10201504102QA patent/SG10201504102QA/en unknown
- 2009-11-19 EP EP15151165.6A patent/EP2889033B1/en active Active
- 2009-11-19 SI SI200931223T patent/SI2540297T1/sl unknown
- 2009-11-19 CN CN2009801546937A patent/CN102281878A/zh active Pending
- 2009-11-19 HU HUE12185913A patent/HUE026815T2/en unknown
- 2009-11-19 PT PT151511656T patent/PT2889033T/pt unknown
- 2009-11-19 KR KR1020117013996A patent/KR20110091549A/ko not_active Ceased
- 2009-11-19 CA CA2894860A patent/CA2894860C/en not_active Expired - Fee Related
- 2009-11-19 EP EP18152484.4A patent/EP3357495B1/en active Active
- 2009-11-19 EP EP12185913.6A patent/EP2540297B1/en active Active
- 2009-11-19 CA CA3017886A patent/CA3017886A1/en not_active Abandoned
- 2009-11-19 NZ NZ613291A patent/NZ613291A/en not_active IP Right Cessation
- 2009-11-19 PL PL15151165T patent/PL2889033T3/pl unknown
- 2009-11-19 JP JP2011537621A patent/JP5272080B2/ja not_active Expired - Fee Related
- 2009-11-19 US US13/129,782 patent/US8642638B2/en not_active Expired - Fee Related
- 2009-11-19 PT PT121859136T patent/PT2540297E/pt unknown
- 2009-11-19 PL PL12185913T patent/PL2540297T3/pl unknown
- 2009-11-19 MX MX2011005270A patent/MX2011005270A/es active IP Right Grant
- 2009-11-19 KR KR1020187002503A patent/KR20180011888A/ko not_active Ceased
- 2009-11-19 DK DK12185913.6T patent/DK2540297T3/en active
- 2009-11-19 SI SI200930466T patent/SI2355822T1/sl unknown
- 2009-11-19 SM SM20180308T patent/SMT201800308T1/it unknown
- 2009-11-19 ES ES12185913.6T patent/ES2541528T3/es active Active
2011
- 2011-05-16 IL IL212921A patent/IL212921A/en not_active IP Right Cessation
- 2011-05-19 CO CO11061800A patent/CO6400190A2/es not_active Application Discontinuation
- 2011-05-19 CL CL2011001178A patent/CL2011001178A1/es unknown
- 2011-05-20 CR CR20110267A patent/CR20110267A/es unknown
- 2011-05-23 EC EC2011011076A patent/ECSP11011076A/es unknown
- 2011-05-31 ZA ZA2011/04044A patent/ZA201104044B/en unknown
2012
- 2012-11-12 US US13/674,290 patent/US8569354B2/en not_active Expired - Fee Related
2013
- 2013-01-07 CY CY20131100013T patent/CY1113671T1/el unknown
- 2013-01-09 SM SM201300003T patent/SMT201300003B/xx unknown
- 2013-04-17 JP JP2013086454A patent/JP5674854B2/ja not_active Expired - Fee Related
- 2013-12-23 US US14/139,178 patent/US20140148479A1/en not_active Abandoned
2014
- 2014-02-07 US US14/175,654 patent/US8815933B2/en not_active Expired - Fee Related
- 2014-06-04 RU RU2014122858A patent/RU2662560C2/ru not_active IP Right Cessation
- 2014-07-17 PH PH12014501629A patent/PH12014501629A1/en unknown
- 2014-10-08 US US14/509,305 patent/US20150265583A1/en not_active Abandoned
- 2014-11-26 JP JP2014238660A patent/JP5869653B2/ja not_active Expired - Fee Related
2015
- 2015-07-01 HR HRP20150711TT patent/HRP20150711T1/hr unknown
- 2015-07-02 CY CY20151100575T patent/CY1116460T1/el unknown
- 2015-07-10 SM SM201500167T patent/SMT201500167B/xx unknown
- 2015-10-12 IL IL242034A patent/IL242034A/en not_active IP Right Cessation
- 2015-10-12 IL IL242035A patent/IL242035A0/en unknown
2016
- 2016-01-07 JP JP2016001812A patent/JP6223480B2/ja not_active Expired - Fee Related
2017
- 2017-07-18 CL CL2017001853A patent/CL2017001853A1/es unknown
- 2017-10-03 JP JP2017193867A patent/JP2018039818A/ja active Pending
- 2017-10-27 US US15/796,475 patent/US20180271844A1/en not_active Abandoned
- 2017-12-06 IL IL256140A patent/IL256140A/en unknown
- 2017-12-14 IL IL256313A patent/IL256313A/en unknown
2018
- 2018-01-03 PH PH12018500023A patent/PH12018500023A1/en unknown
- 2018-05-25 CL CL2018001420A patent/CL2018001420A1/es unknown
- 2018-06-18 HR HRP20180942TT patent/HRP20180942T1/hr unknown
- 2018-06-20 CY CY20181100638T patent/CY1121607T1/el unknown
- 2018-07-11 RU RU2018125456A patent/RU2018125456A/ru unknown
2019
- 2019-11-22 JP JP2019210985A patent/JP2020040977A/ja active Pending

Also Published As

Publication number	Publication date
JP5272080B2 (ja)	2013-08-28
HUE026815T2 (en)	2016-07-28
IL256140A (en)	2018-02-28
IL256313A (en)	2018-02-28
ZA201104044B (en)	2012-11-28
CO6400190A2 (es)	2012-03-15
US20130137717A1 (en)	2013-05-30
NZ613291A (en)	2014-11-28
US20140148479A1 (en)	2014-05-29
KR20180011888A (ko)	2018-02-02
CL2017001853A1 (es)	2018-05-11
CA2894860A1 (en)	2010-05-27
CN102281878A (zh)	2011-12-14
WO2010059844A1 (en)	2010-05-27
EP2889033B1 (en)	2018-03-21
ES2396300T3 (es)	2013-02-20
EP2355822B1 (en)	2012-10-10
PT2889033T (pt)	2018-06-18
RU2018125456A (ru)	2020-01-13
US8642638B2 (en)	2014-02-04
JP5674854B2 (ja)	2015-02-25
EP2540297A1 (en)	2013-01-02
IL212921A0 (en)	2011-07-31
PT2540297E (pt)	2015-08-26
IL242034A0 (en)	2015-11-30
EP2889033A1 (en)	2015-07-01
ES2673016T3 (es)	2018-06-19
MY173229A (en)	2020-01-07
PH12014501629B1 (en)	2016-01-18
PL2355822T3 (pl)	2013-03-29
IL212921A (en)	2015-11-30
CA2744278C (en)	2015-09-08
MX2011005270A (es)	2011-08-03
MY159826A (en)	2017-02-15
CA2894860C (en)	2018-11-06
JP2020040977A (ja)	2020-03-19
RU2662560C2 (ru)	2018-07-26
IL242035A0 (en)	2015-11-30
CA3017886A1 (en)	2010-05-27
JP5869653B2 (ja)	2016-02-24
DK2540297T3 (en)	2015-07-13
US8569354B2 (en)	2013-10-29
PL2540297T3 (pl)	2015-12-31
PH12018500023A1 (en)	2019-07-15
SG10201504102QA (en)	2015-06-29
AU2009316557B2 (en)	2015-08-27
IL242034A (en)	2017-12-31
HRP20130007T1 (hr)	2013-01-31
JP2013166771A (ja)	2013-08-29
US20150265583A1 (en)	2015-09-24
CL2018001420A1 (es)	2018-09-28
CY1121607T1 (el)	2020-05-29
CN105687190A (zh)	2016-06-22
SI2889033T1 (en)	2018-08-31
US20180271844A1 (en)	2018-09-27
US8815933B2 (en)	2014-08-26
CN105687191A (zh)	2016-06-22
US20110288119A1 (en)	2011-11-24
CR20110267A (es)	2011-10-13
SMT201500167B (it)	2015-09-07
PH12014501629A1 (en)	2016-01-18
DK2355822T3 (da)	2013-01-28
US20140155430A1 (en)	2014-06-05
TR201807944T4 (tr)	2018-06-21
KR20140146216A (ko)	2014-12-24
RS52583B (sr)	2013-04-30
EP2540297B1 (en)	2015-04-08
JP2012509347A (ja)	2012-04-19
JP6223480B2 (ja)	2017-11-01
RU2011124515A (ru)	2012-12-27
EP2355822A1 (en)	2011-08-17
CA2744278A1 (en)	2010-05-27
RU2014122858A (ru)	2015-12-10
HK1158520A1 (en)	2012-07-20
BRPI0922057A2 (pt)	2015-12-15
DK2889033T3 (en)	2018-07-02
JP2018039818A (ja)	2018-03-15
EP3357495A1 (en)	2018-08-08
AU2009316557A1 (en)	2010-05-27
SMT201300003B (it)	2013-05-06
CL2011001178A1 (es)	2011-10-14
SI2540297T1 (sl)	2015-08-31
CY1113671T1 (el)	2016-07-27
ECSP11011076A (es)	2011-09-30
HUE037938T2 (hu)	2018-09-28
PL2889033T3 (pl)	2018-10-31
HRP20180942T1 (hr)	2018-08-10
KR20110091549A (ko)	2011-08-11
SMT201800308T1 (it)	2018-09-13
RU2532327C2 (ru)	2014-11-10
SI2355822T1 (sl)	2013-02-28
EP3357495B1 (en)	2019-12-25
JP2015083574A (ja)	2015-04-30
PE20110711A1 (es)	2011-10-11
CY1116460T1 (el)	2017-03-15
JP2016128442A (ja)	2016-07-14
NZ593467A (en)	2013-07-26
PT2355822E (pt)	2013-01-14
HRP20150711T1 (hr)	2015-08-14
ES2541528T3 (es)	2015-07-21

Publication	Publication Date	Title
SMT201800308T1 (it)	2018-09-13	Trattamento di sintomi negativi di schizofrenia con (r)-7-cloro-n-(chinuclidin-3-il benzo[b]tiofen-2-carbossammide e relativi sali farmaceuticamente accettabili
NZ603625A (en)	2014-10-31	A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate
IL211279A (en)	2015-03-31	Use of the tspan12 antagonist in the preparation of a blood vessel inhibition drug
HUP0700369A2 (en)	2009-04-28	Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
HUP0700370A2 (en)	2009-04-28	Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment of acute mania
EP2431362A4 (en)	2012-10-10	3- (4-AMINOPHENYL) -2-FURANCARIC ACID DERIVATIVE AND PHARMACEUTICAL ACCEPTABLE SALT THEREOF
EP2121729A4 (en)	2013-07-31	PHARMACEUTICAL, SUBSTANTIVE SALTS OF THYMODEPRESSINE AND METHOD FOR THE PRODUCTION THEREOF